Prilenap H

Quick links to important sections

Prilenap H

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prilenap H

Property Description
Active Ingredients Enalapril maleate, Hydrochlorothiazide
Form Oral tablet
Pharmacological Class ACE Inhibitor and Diuretic (Combined)
Common Use Systematic Antihypertensive Therapy
Origin Synthetic

Prilenap H is a prescription-only medicine that is classified as a Fixed-Dose Combination (FDC) antihypertensive agent, specifically designed for the systematic management of high blood pressure. This medication is a synthetic pharmaceutical product presented as an oral tablet, and it requires a doctor's prescription for use.


What Type of Antihypertensive Agent is Prilenap H?

Prilenap H is a dual-action antihypertensive agent, combining an ACE inhibitor with a diuretic into a single tablet formulation.

The drug belongs to the pharmacological class of ACE Inhibitors and Diuretics (combined), a categorization reflecting its compound nature. This FDC utilizes two classes of medication to address essential hypertension. Unlike therapeutic regimens that require taking two medications separately, Prilenap H is specifically positioned to simplify antihypertensive therapy, ensuring the immediate, simultaneous delivery of both key agents in one oral tablet. This streamlined approach is often reserved for adult patients whose blood pressure is not adequately controlled by a single agent.

The Dual Composition: Enalapril and Hydrochlorothiazide

The core composition of Prilenap H features two principal active ingredients: Enalapril maleate and Hydrochlorothiazide.

The first component, Enalapril maleate, functions as an Angiotensin-Converting Enzyme (ACE) inhibitor, a drug class primarily used to cause vasodilation by relaxing the blood vessels. The second component, Hydrochlorothiazide (HCTZ), functions as a thiazide diuretic, assisting the kidneys in removing surplus salt and water from the body. This specific combination therapy is one of several widely utilized synthetic pairings that target distinct cardiovascular system functions.

General Purpose and Action of the Combination Therapy

The general purpose of Prilenap H is to reduce hypertension by combining the effects of vasodilation and volume depletion.

This medicine achieves its fundamental therapeutic goal through two complementary physiological actions. Enalapril promotes the relaxation of blood vessels, lowering the resistance to blood flow, while Hydrochlorothiazide initiates a diuretic action that results in the volume depletion of circulating fluid. This synergistic dual effect helps to alleviate the overall workload on the cardiovascular system, forming the basis of its primary role in long-term blood pressure control.

Regulatory References

  1. DailyMed: Enalapril Maleate and Hydrochlorothiazide

What side effects are possible with Prilenap H?

Possible Side Effects and Safety Information

The safety profile of Prilenap H, a combination of Enalapril and Hydrochlorothiazide, is officially documented by government health authorities, classifying adverse reactions by frequency and the body system affected. These classifications establish the expected risk profile of the medication, strictly based on regulatory data.

Documented Adverse Reactions

The most frequently reported adverse reactions, classified as Very Common or Common in regulatory documents, include dizziness, headache, a dry and persistent cough (associated with the ACE inhibitor component), fatigue, asthenia (weakness), and nausea. Effects on the vascular system, such as orthostatic hypotension (low blood pressure upon standing), are also listed as common.

Serious Safety Considerations

The official labeling documents the occurrence of serious adverse reactions, which are rare but clinically significant. These include angioedema (a potentially life-threatening swelling of the face, lips, tongue, or larynx), acute renal failure, and severe hepatic failure or necrosis. Additionally, severe blood disorders, such as neutropenia or agranulocytosis, are officially reported.

Population-Specific and Time-Related Safety Notes

Official regulatory sources note specific safety constraints. The medicine is contraindicated in pregnancy due to the documented risk of fetal injury and death. Furthermore, certain effects, such as acute transient myopia (nearsightedness) and acute angle-closure glaucoma, are documented as potential effects that may occur within hours of initiating therapy. The product labeling also includes high-level safety restrictions regarding use with certain other drug classes or in patients with a history of angioedema related to a previous ACE inhibitor treatment.

Overdose and Emergency Response

Overdose: When to Seek Help

Official regulatory information for Prilenap H (Enalapril/Hydrochlorothiazide) describes specific manifestations and the required emergency response in the event of an overdose.

Immediate medical attention is necessary if an overdose is suspected or if symptoms of marked toxicity develop.

Feature Documented Regulatory Statement
Primary Manifestations Symptoms are primarily characterized by marked hypotension (severe drop in blood pressure) and significant fluid and electrolyte losses.
Serious Outcomes Potential for circulatory collapse (shock), stupor, and development of renal failure due to sustained low blood pressure.
Physiological Systems Affects the Cardiovascular System (hypotension, bradycardia) and Renal System (fluid/electrolyte balance, renal function).

Emergency Response

The primary emergency response documented in official labeling is focused on immediate measures to counteract the severe drop in blood pressure and restore bodily fluids. Management involves placing the individual in a supine position and, if required, administering an intravenous infusion of normal saline to raise blood pressure.

If marked hypotension or signs of circulatory compromise are observed, emergency medical services must be contacted immediately. The official overdose profile emphasizes that the severe consequences of overdose are directly related to the cardiovascular effects of the medication.

Therapeutic Uses of Prilenap H

What Prilenap H Treats: Main Uses and Benefits


The core purpose of this medication is the systematic management of chronic high blood pressure. A consistent reduction in blood pressure may assist with reducing the risk of progressive stress on vital organs.

Systematic Control of Uncontrolled High Blood Pressure

Prilenap H is primarily used for the long-term systematic management of chronic essential hypertension in adults. This fixed-dose combination generally helps address the symptom clusters related to systemic imbalance and noticeable physiological strain that are part of high blood pressure. This approach is commonly used in conditions where monotherapy is no longer sufficient for managing the underlying condition, moving to a dual-intervention strategy. The primary clinical indications for this combination generally include: essential hypertension and use in patients requiring dual-agent therapy for blood pressure control.

Protecting Against Major Cardiovascular Events

This combination is often applied in scenarios where additional management of discomfort is required to achieve and maintain therapeutic goals. Maintaining stable blood pressure may assist with reducing the risk of severe cardiovascular events, including strokes and heart attacks, which represents a key long-term benefit for patient well-being. By combining two necessary components, it helps support functional stability and supports patients during difficult episodes by easing the organizational burden of a dual-drug regimen.


Quick Fact: Relief for Chronic Vascular Strain

This medication is applied in addressing the systemic imbalance that creates chronic high blood pressure, which represents a key long-term benefit for patient well-being.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Prilenap H — Official Regulatory Information

This fixed-dose combination is primarily intended for adult patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy. Its use is strictly defined by regulatory guidelines based on population and condition-specific exclusions.

Eligibility Scope Official Regulatory Status
Populations for whom use is allowed Adult patients with essential hypertension.
Populations for whom use is not recommended Children and adolescents under 18 years of age; Lactating women.
Populations for whom use is contraindicated History of angioedema (ACEI-related or hereditary); Anuria; Hypersensitivity to components or sulfonamide-derived drugs; Second and third trimesters of pregnancy.
Age and Condition Rules Official Regulatory Status
Age-related eligibility Pediatric (<18 years): Not recommended; safety and efficacy are not established.
Organ-function eligibility Contraindicated in severe renal failure and severe hepatic impairment. Mild to moderate impairment requires restricted use and close monitoring.
Physiological status Use is prohibited when pregnancy is detected in the second or third trimesters; must be discontinued in the first trimester. Volume depletion must be corrected before treatment initiation.

The regulatory basis classifies this medicine as Contraindicated for specific high-risk groups to prevent severe reactions, ensuring its administration remains within narrowly defined, officially established population limits.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Prilenap H (Enalapril/Hydrochlorothiazide) describes several documented interaction patterns that require specific restrictions or prohibitions.

Contraindicated Combinations and Mandatory Separation

Co-administration with Sacubitril/Valsartan (neprilysin inhibitors) is formally contraindicated due to the high risk of angioedema; a mandatory 36-hour separation window must be observed before or after administering these agents. Additionally, the combination with Aliskiren is contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m²).

Pharmacodynamic and Electrolyte-Altering Interactions

Interactions with substances that affect fluid and electrolyte balance are well-documented. Co-administration with Potassium-Sparing Diuretics (e.g., spironolactone) and Potassium Supplements carries an additive risk of hyperkalemia (high potassium levels). The use of Lithium concurrently increases the risk of lithium toxicity as the diuretic component reduces its renal clearance. Furthermore, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are documented to reduce the blood pressure-lowering effect of the Hydrochlorothiazide component.

Exposure and Substance Interactions

Certain substances interfere with drug absorption. Cholestyramine and Colestipol resins impair the absorption of the Hydrochlorothiazide component, reducing systemic exposure. Alcohol is documented to have an additive effect in lowering blood pressure, which can potentiate orthostatic hypotension. Specific mTOR inhibitors (e.g., sirolimus) and Vildagliptin are also associated with an increased risk of angioedema.

Mechanism of Action

Prilenap H is a fixed-dose combination containing enalapril and hydrochlorothiazide.

Enalapril, a prodrug, undergoes hepatic hydrolysis into its active metabolite, enalaprilat, which acts as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), primarily located in vascular tissue. This inhibition prevents the ACE-mediated conversion of inactive Angiotensin I into the potent vasoconstrictor, Angiotensin II. The resulting decrease in circulating and tissue Angiotensin II reduces vasopressor activity and attenuates aldosterone secretion from the adrenal cortex. Reduced aldosterone decreases sodium and water reabsorption in the renal collecting duct. Concurrently, ACE inhibition reduces the degradation of the vasodilatory peptide bradykinin.

Hydrochlorothiazide functions as a diuretic, selectively accumulating in the kidney and acting as an inhibitor of the sodium-chloride cotransporter (NCC) in the luminal membrane of the distal convoluted tubule. NCC inhibition blocks the reabsorption of approximately 5-10% of filtered sodium and chloride, leading to increased urinary excretion of these ions and water. This dual-mechanism action results in reduced systemic peripheral vascular resistance and decreased intravascular volume, which collectively modulate circulatory dynamics.

Dosage and Administration Information

How to Use Prilenap H

Administration Principles

Prilenap H is administered orally as a Fixed-Dose Combination (FDC) tablet containing Enalapril maleate and Hydrochlorothiazide. This medication is specifically intended for the continuation of treatment in adult patients whose blood pressure is not adequately controlled by monotherapy, or as a replacement therapy following successful dose titration of the individual components. It is not indicated for use as initial therapy.

The standard pattern is to take one tablet once daily. The tablet may be taken with or without food, as the presence of food does not significantly affect its absorption. The maximum official daily dose of the FDC must not exceed the equivalent of 20 mg Enalapril and 50 mg Hydrochlorothiazide. While once daily is standard, the total daily dose may be administered in two divided doses if the antihypertensive effect diminishes toward the end of the dosing interval.

Procedural Guidelines

The tablet must be swallowed whole and should not be crushed or split to maintain the integrity of the combined dose, particularly the higher strength 10 mg/25 mg tablet. If a dose is missed, it should be skipped entirely, and the next scheduled dose should be taken at the regular time; doubling the next dose is not permitted.

Population-Specific Use Constraints

Official instructions define usage constraints based on patient characteristics. The FDC is not recommended for patients under 18 years of age, as safety and efficacy have not been established. Use is also restricted in cases of severe renal impairment (Creatinine Clearance ≤ 30 mL/min). For older adults or patients with moderate renal impairment, titration using the enalapril component alone is typically recommended prior to commencing the FDC therapy.

Recent Clinical Evidence

Research evidence / Overview of studies for Prilenap H


Evidence for use in Systematic Management of High Blood Pressure

The research on Prilenap H (Enalapril/HCTZ fixed-dose combination) was studied for the systematic management of chronic essential hypertension in adults. The evidence base primarily includes short-term Randomized Controlled Trials (RCTs) that were evaluated in adults diagnosed with high blood pressure. These studies focused on measuring the mean change in Systolic and Diastolic Blood Pressure (BP) and the rate at which BP measurements moved toward predefined protocol targets. Findings describe patterns observed in the studies where the combination provided measured changes in BP readings. However, the follow-up durations were limited in many trials, meaning long-term effects are not fully established specifically for the FDC itself.


Evidence for use in Dual-Agent Therapy

The rationale for Prilenap H was studied for its use as a dual-agent therapy, particularly for patients not controlled by monotherapy. Research examined the approach of combining an ACE inhibitor and a diuretic. Studies explored the measurements generated by this approach versus using a single agent only. The findings indicate that patterns in blood pressure measurements may differ from those observed with monotherapy. Bioequivalence studies describe patterns related to the delivery of the two agents when administered together versus individually. Comparative evidence directly against all other dual-agent combinations is lacking.


Long-term studies and follow-up

Studies monitored measurements reflecting systemic or functional imbalance, such as the occurrence of major cardiovascular events like stroke. Long-term data is drawn from trials utilizing the component drug classes. These findings help contextualize how the observed long-term blood pressure measurements may relate to patterns in the occurrence of major cardiovascular events. Systematic reviews indicate that direct evidence for the FDC's effect on endpoints like all-cause mortality is limited, and the body of evidence does not provide definitive conclusions.


Evidence in special populations and subgroups

Prilenap H was evaluated in specific patient groups, including those with moderate to severe hypertension and those not controlled by monotherapy. Research has also examined how measurements related to physiological strain were reported across different subgroups, including specific analyses involving Black hypertensive patients. Research describes observations where a differential average response to the ACE inhibitor component was observed in some studies. Therefore, data for certain groups remain insufficient to draw broad conclusions.

Frequently Asked Questions (FAQ)

Common questions about Prilenap H (FAQ)


Q: How quickly should I expect Prilenap H to start working?

The active component, enalaprilat, reaches its highest concentration in the blood within approximately 4 to 6 hours after taking a dose. The diuretic component, hydrochlorothiazide, is absorbed rapidly. While the medicine has pharmacokinetic activity within hours, the full effect on blood pressure control is intended to be seen over time.


Q: What happens if I stop taking Prilenap H suddenly?

Regulatory guidance advises against discontinuing the medicine without first consulting a healthcare professional. High blood pressure is a chronic condition, and stopping treatment abruptly may disrupt the management of blood pressure. Continued adherence is generally described as necessary for control of the condition.


Q: Does Prilenap H cause weight gain?

Official documents list changes in weight, including both loss and gain, as possible but infrequently reported adverse reactions. The specific occurrence of weight gain is not detailed as a common effect of this medicine in the primary regulatory information.


Q: Does Prilenap H affect blood sugar levels?

Yes, official information states that the hydrochlorothiazide component (the diuretic) may affect how the body tolerates glucose, which is a measure of blood sugar. Official documentation notes that this effect may require consideration for patients using antidiabetic medicines.


Q: Does Prilenap H cause an increased need to urinate?

Yes, the medicine contains a diuretic, hydrochlorothiazide, which acts to increase the excretion of salt and water through the kidneys. This effect is intended to lower blood pressure and may result in an increased flow of urine or a need to urinate more frequently, especially when treatment begins.


Q: Does Prilenap H affect a person's potassium levels?

Prilenap H can affect the amount of potassium in the blood. The two active ingredients have opposing effects: the ACE inhibitor component can sometimes lead to high potassium, while the diuretic component can lead to low potassium. For this reason, official information describes the need for regular blood testing to monitor these levels.


Q: Can older adults use Prilenap H safely?

The medicine is widely used by older adults for high blood pressure. While appropriate studies have not found age-specific problems that limit its usefulness, regulatory guidelines note that older age may be associated with reduced kidney, liver, or heart function. Due to the potential for reduced organ function in older adults, specific titration protocols or caution are described in official guidance prior to commencing the fixed-dose combination therapy.


Q: What are the long-term effects or safety profile of Prilenap H?

The medicine is indicated for the long-term, systematic management of chronic high blood pressure. Regulatory documents describe known risks associated with long-term use, including the risk of non-melanoma skin cancer with prolonged exposure to the hydrochlorothiazide component. Continuous monitoring is described as necessary to manage these documented risks.


Q: Can Prilenap H cause a persistent cough?

A dry and persistent cough is listed as a very common side effect of the ACE inhibitor component of the medicine. Official regulatory information notes that this cough typically resolves following discontinuation of the medicine.


Q: Is it normal to have mild headaches when starting Prilenap H?

Headache and dizziness are listed as common side effects. Patient guidance documents often indicate that these symptoms are most likely to be seen when a person first starts treatment or after a dose increase. These effects may lessen or disappear after the first few weeks as the body adjusts.


Q: Is there a risk of low blood pressure (hypotension) with Prilenap H?

Yes, regulatory warnings advise of the risk of symptomatic hypotension (low blood pressure), which is more likely in patients who are dehydrated or have existing salt depletion. Dizziness or light-headedness, especially when quickly changing position (like standing up), are documented signs of this effect.


Q: Is Prilenap H used for heart failure or just high blood pressure?

The official indication (approved use) for the combination product Prilenap H (enalapril/hydrochlorothiazide) is the treatment of essential hypertension (high blood pressure). The Enalapril component alone is used for heart failure, but the fixed-dose combination product is approved only for high blood pressure.


Q: What are the signs of a serious, rare side effect of Prilenap H?

One serious, rare side effect documented in official warnings is angioedema, which is rapid swelling. Signs include swelling of the face, lips, tongue, or throat, or the sudden onset of difficulty breathing or swallowing. Immediate medical attention is described as necessary if any of these signs occur.


Q: Is Prilenap H suitable for people with a history of gout?

Regulatory documents state that the diuretic component may increase the level of uric acid in the blood, which is the cause of gout. This increase may trigger or worsen episodes of gout. Regulatory documents describe the need for cautious use for patients with a history of the condition.


Q: Can Prilenap H be used for other conditions besides high blood pressure?

The medicine is officially approved and indicated only for the treatment of essential hypertension (high blood pressure) in adults. Using it for any other condition is not described in the official product labeling.


Q: Is Prilenap H the same as other 'H' combination drugs?

Prilenap H is a specific combination of enalapril (an ACE inhibitor) and hydrochlorothiazide (the 'H' diuretic). While other combination drugs also contain hydrochlorothiazide, they are paired with different types of blood pressure medicines and are therefore not the same.


Q: Are there common but minor side effects that often go away?

Official patient guidance indicates that common side effects such as fatigue, dizziness, and headache may be felt when first starting the treatment. These minor effects are temporary and often lessen or disappear after the first few weeks as the body adjusts to the medicine.


Q: What foods or supplements should I be careful about with Prilenap H?

Regulatory documents specifically advise caution regarding potassium-containing salt substitutes and potassium supplements. This is because the ACE inhibitor component can increase the risk of developing dangerously high potassium levels (hyperkalemia) in the blood.


Q: Can Prilenap H be used by people with kidney problems?

The medicine is contraindicated (not allowed) for use in patients with severe renal impairment (very poor kidney function). For those with moderate impairment, close medical monitoring is described as necessary due to the risk of worsening kidney function.


Q: Is Prilenap H safe for people with asthma?

Regulatory documentation suggests that a history of asthma or other allergies may increase the likelihood of experiencing a hypersensitivity reaction to the medicine. Official guidance describes the need for cautious use and close medical supervision for patients with asthma.


Q: What kind of research has been done on Prilenap H?

Official documents summarize research that primarily consists of short-term randomized controlled trials (RCTs). These studies were focused on measuring the combination's efficacy in lowering blood pressure in adults diagnosed with essential hypertension.


Q: Is there a generic version of Prilenap H available?

Yes, regulatory databases confirm that generic versions of the fixed-dose combination containing enalapril maleate and hydrochlorothiazide are commercially available.


Q: How long is Prilenap H typically prescribed for?

High blood pressure is considered a chronic, non-curable condition. The medicine is intended for the long-term systematic management and continuation of treatment to maintain blood pressure control over time.


Q: What is the shelf life or proper way to store Prilenap H?

The medicine must be kept in its original, tightly closed container and stored at Controlled Room Temperature (typically 15 C to 30 C). It must be protected from excess heat and moisture to maintain its potency.


Q: Does Prilenap H affect athletic performance or exercise?

The diuretic component, hydrochlorothiazide, is officially classified as a prohibited substance by the World Anti-Doping Agency (WADA) in many competitive sports due to its masking potential. Patients who participate in professional or competitive athletics are directed to consult official anti-doping regulations regarding this classification.


Q: Why is regular blood testing needed while taking Prilenap H?

Regular laboratory tests are necessary to monitor levels of important minerals, such as potassium, and to check kidney function and liver function. This is because the medicine can cause changes in these blood values, and close medical monitoring is described as necessary.


Q: Can Prilenap H affect my ability to drive or operate machinery?

Due to the possibility of side effects like dizziness or light-headedness, official warnings advise caution when driving or operating machinery. This is especially true when starting treatment until an individual knows how the medicine affects them.


Q: Does Prilenap H have any effect on cholesterol?

Official information indicates that the diuretic component, hydrochlorothiazide, may cause minor or reversible increases in total cholesterol and triglyceride levels in the blood. These effects are typically managed through continued monitoring.


Q: Is the evidence for Prilenap H based on large clinical trials?

The evidence supporting the combination is drawn from randomized controlled trials (RCTs) which describe its efficacy in lowering blood pressure. The research base utilizes studies of the combination product itself, as well as the well-established component drug classes.


Q: Is Prilenap H commonly prescribed for certain ethnic groups?

Official documentation notes that a differential average response to the ACE inhibitor component has been observed in some studies involving Black hypertensive patients. This clinical observation is part of the information that may guide prescribing decisions.


Q: Can women who are planning pregnancy use Prilenap H?

Official documentation describes that the medicine is generally avoided for women who are planning a pregnancy. It is contraindicated in the second and third trimesters, and must be discontinued immediately if pregnancy is detected due to documented risks to the developing fetus.


Q: Does Prilenap H interact with herbal supplements?

While specific herbal supplements are not universally listed, official documents require a review of all co-administered substances. Of specific concern are herbal products that contain or affect potassium levels, as this could lead to the complication of hyperkalemia.

How should Prilenap H be stored and disposed of?

How to Store and Dispose of Prilenap H

Prilenap H (Enalapril Maleate and Hydrochlorothiazide) must be stored and disposed of according to strict regulatory guidelines to ensure product integrity and safety.


Storage Requirements

The tablets must be stored at Controlled Room Temperature, generally defined as between 15 C and 30 C (59 F and 86 F). Storage must be away from excess heat and moisture, and the medicine should not be frozen. Keep the medication in the original container, ensuring it is tightly closed.

For child safety, Prilenap H must be stored out of the sight and reach of children, and safety caps should always be locked.


Disposal Instructions

Expired or unused medicine must be discarded. Consult a healthcare professional or pharmacist regarding local drug take-back programs. If household disposal is necessary, remove the tablets from the container, mix with an unappealing substance like used coffee grounds, and place the mixture in a sealed bag before throwing it into the trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prilenap H found in:

A-Z Index: